Crews Bank & Trust Takes Position in Danaher Co. (NYSE:DHR)

Crews Bank & Trust bought a new stake in Danaher Co. (NYSE:DHR) during the 4th quarter, HoldingsChannel reports. The fund bought 2,399 shares of the conglomerate’s stock, valued at approximately $551,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Fort Pitt Capital Group LLC boosted its holdings in shares of Danaher by 3.2% in the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after acquiring an additional 7,421 shares in the last quarter. Good Life Advisors LLC purchased a new stake in Danaher during the third quarter worth about $217,000. ORG Partners LLC boosted its holdings in Danaher by 1,212.8% during the fourth quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after buying an additional 2,559 shares in the last quarter. Harvest Portfolios Group Inc. boosted its holdings in Danaher by 1.2% during the third quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after buying an additional 2,465 shares in the last quarter. Finally, Stifel Financial Corp boosted its holdings in Danaher by 1.3% during the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock worth $235,583,000 after buying an additional 11,216 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $223.16 on Friday. Danaher Co. has a one year low of $221.34 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a 50 day moving average price of $235.89 and a 200 day moving average price of $253.45. The firm has a market capitalization of $161.19 billion, a price-to-earnings ratio of 42.59, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same quarter last year, the business earned $2.09 earnings per share. Sell-side analysts anticipate that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.48%. Danaher’s dividend payout ratio is currently 20.61%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on DHR shares. Stephens reissued an “overweight” rating and set a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. KeyCorp boosted their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Stifel Nicolaus upped their price target on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.